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Numerous studies have shown that early screening for the presence of pre-cancerous colon polyps and their
subsequent removal decreases the risk of developing colon cancer. Colonoscopy is currently the most effective
screening method, but due to the invasive nature of the procedure many patients avoid forgo testing. Futhermore,
the procedure itself requires perfect execution by the gastroenterologist. Against this backdrop, a non-invasive
blood screening method for the detection of colon polyps that has higher sensitivity than current screening
techniques would be beneficial in the early identification of patients at risk for colon cancer. A prospective,
double-blinded, controlled clinical study was designed to demonstrate the diagnostic performance of Polyp Specific
Polymer analysis, a novel laboratory methodology. The primary objective of this clinical trial was to estimate the
diagnostic accuracy of the Polyp Specific Polymer analysis for colon polyps using colonoscopy and histological tests
as the diagnostic accuracy standards. Secondary objectives of this trial included estimating positive and negative
predictive values for colon polyps, investigating reliability, determining covariates influencing diagnostic accuracy
and obtaining absolute and relative frequencies of valid test results.
In patients undergoing screening colonoscopy and histology examination, a sensitivity of 72.4% and a specificity of
62.3% could be proven.
These results indicate that using this improved screening method it is possible to effectively identify the highest-risk
candidates for endoscopy, thereby advancing the goal of decreasing the incidence or mortality of colorectal cancer
in the selected population. Moreover, this diagnostic tool has potential socio-economic implications, conserving
healthcare resources by enabling higher patient selectivity for endoscopy and eventual transfer to curative
prevention via polypectomy.
By combining the best-established low-risk screening elements together with a validated, highly sensitive blood test
as described in this study, a steadfast increase in the estimation of colorectal cancer-risk before colonoscopy can be
expected.
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Colon polyps are mucosal lesions that protrude into the
lumen of the large intestine and are highly prevalent in
Western populations in people over 55 years of age [1].
There are four types of colonic polyps: the most import-
ant are adenomatous polyps, which are implied as pre-
cursors for colorectal cancer (CRC), the second leading
cause of cancer related deaths in Western countries.
One of the most insidious problems regarding colon
polyps is that the majority of affected persons do not* Correspondence: luis.gomez@indago-group.com
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reproduction in any medium, provided the oractually display any adverse symptoms. Numerous stud-
ies have indicated that early screening for the presence
of pre-cancerous colon polyps and their subsequent re-
moval decreases the probability of colon cancer and as-
sociated mortality [2,3].
There are various diagnostic methods available to detect
colonic polyps. These include: fecal occult blood testing
(FOB), virtual colonoscopy, sigmoidoscopy, colonoscopy,
and the combination of barium enema and sigmoidos-
copy. An estimated 1-5% of patients over 55 years of age
have a positive fecal occult blood test, approximately
2-10% of these have cancer while 20-30% have adenomas
or polyps [1,4]. Colonoscopy, which allows the physiciantd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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polyps for analysis, is the most effective screening method
[2]. However, because of the invasive nature of the proced-
ure, which must be performed by qualified physicians in a
clinical setting, many patients that would potentially bene-
fit from the procedure abstain from testing.
The progression of adenoma to carcinoma represents
a significant public health problem and early screening
for and removal of colon polyps has been demonstrated
to reduce the risk of death from colorectal cancer [4]. A
non-invasive blood or serum-based screening method
for the detection of colon polyps that has a higher sensi-
tivity and specificity than current screening techniques
and that could be carried out with conventional blood
tests would be beneficial in early identification of pa-
tients at risk for colon cancer [5].
Polyp Specific Polymer (PSP) analysis is a novel la-
boratory methodology for the diagnosis of human dis-
eases that can detect various pathological changes in a
variety of organs and organ systems [3]. PSP analysis de-
tects aberrant composition of whole blood providing in-
formation about organ function and their disorders. As
yet, such broad information could not be detected or
could only be detected with considerable effort from
serum samples PSP methodology is based on the micro-
scopic analysis of individual nanoparticles from dena-
tured whole blood samples. The resulting polymeric
structures can provide information about cell functions
and disorders.
Currently, PSP analysis has been performed in the form
of a generalized, empirically proven analysis process. To
fulfill the requirements of standardization and accredit-
ation, the structures underlying Polyp Specific Polymer
(PSP) analysis must be registered by image acquisition [6].
In view of the potential of such methodology in the
diagnosis of colon cancer, we have evaluated the diagnos-
tic potential of Polyp Specific Polymer analysis (PSP) in a
prospective, double-blinded, controlled clinical study.
Materials and methods
Trial design
The double-blind and multi-centric study was designed as
a prospective, open clinical diagnostic study in Germany.
The deciding inclusion criterion was the participation in a
screening for polyposis and with no known disease. Pa-
tients over 50 years of life were included according to the
recommendations of BMG (Federal Ministry of Health).
The study was conducted in parallel with a screening col-
onoscopy according to current screening guidelines [7].
From September 2011 to May 2012, 233 patients entered
the study. 9 physicians recruited the patients and recorded
clinical data (n = 233), performed colonoscopy and biopsy
(n = 216; abbreviated in results as RS), and took blood
samples (n = 233). Medical examinations were carried outon 233 patients. 45 patients dropped out during statistical
analysis (RS and PSP-test not available (N = 3); RS not
available (N = 14); RS: D + and PSP-test not available (N =
22); RS: D- and PSP-test not available (N = 6)). So the ana-
lysis set has an amount of 188.
The study was deemed a phase III trial according to the
criteria of the German Society on Medical Informatics, Bi-
ometry, and Epidemiology (GMDS; http://www.gmds.de)
allowing direct estimation not only of sensitivity and spe-
cificity, but also of predictive values. The primary objective
of this clinical trial was to estimate the diagnostic accuracy
(sensitivity and specificity) of PSP analysis for colon polyps
using colonoscopy as a diagnostic accuracy standard.
Secondary objectives of this trial included estimating posi-
tive and negative predictive values for colon polyps, inves-
tigating reliability, determining covariates influencing
diagnostic accuracy, and obtaining absolute and relative
frequencies of valid test results.
The study was registered with German authorities
(Deutsches Institut für Medizinische Dokumentation und
Information, DIMDI) under Number 00006854. The
local ethics committee (Ethikkomission Landesärztekam-
mer Sachsen) approved the study under Number EK-BR-
55/10-1 and all participants signed the informed consent
documentation. Nine medical doctors in private practice
recruited patients and performed colonoscopy and bi-
opsy. Biopsy specimens were analyzed in regional path-
ology centers. Blinding, de-blinding, and randomization
were carried out at the Translational Centre for Regen-
erative Medicine (TRM) of the University of Leipzig.
Statistical evaluations and data analysis were performed
by ACOMED statistics (http://www.acomed-statistics.
com).
The parallel colonoscopy could be performed on the
day of blood sampling or later, whereby a maximum
time difference of 2 weeks was allowed. The following
parameters were evaluated during the screening visit:
sex, name, date of birth, blood pressure, heart frequency.
Inclusion and exclusion criteria are listed below.
Inclusion criteria:
 Informed consent provided.
 Patient was capable of providing an adequate health
history.
 Age 50 years or older at the time of colonoscopy
(colorectal screening guideline eligible).
 Accessible for blood withdrawal prior to the start of
bowel preparation for colonoscopy.
 First large bowel endoscopy in patient lifetime.
Exclusion criteria:
 Terminal illness.
 Presence of severe psychiatric symptoms.
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2 years.
 Anorectal bleeding or hematochezia within the last
6 months for which the patient sought medical
attention.
 Known iron deficiency anemia within the last
6 months for which the patient sought medical
attention.
 Previous history of colorectal polyps or CRC.
 High risk for colorectal cancer (2 or more relatives
with CRC; 1 or more relative(s) < 50 years with
CRC; known HNPCC or FAP).
 Myeloproliferative disease.
 Lack of compliance.
The colonoscopy results combined with biopsy histo-
logical examination were used as the diagnostic accuracy
standard (DAS) for the primary objective (i.e. detection
of adenomatous polyps). The results were classified as
below:
 Colonoscopy negative and histology negative (DAS
negative).
 Colonoscopy positive and histology negative (DAS
negative).
 Colonoscopy positive and histology positive, (DAS
positive).
Laboratory diagnostics
PSP methodology is based on the microscopic analysis
of thermal denatured, resolved and crystallized whole
blood samples.
The Polyp Specific Polymer (PSP) test has been used to
analyze characteristic changes in whole blood samples after
prior thermal decomposition and crystallization in the
nanoparticle range [8]. Analysis of the results requires a
quantitative and qualitative description of crystallization
patterns and intensities similar to X-ray crystallography/
structure analysis [9]. All steps in the procedure are accur-
ately described using a validated Standard Operating Pro-
cedure (SOP). Evaluations were carried out by collaborators
using currently existing clinical comparison standards. PSP
analysis involves the processing of large amounts of data.
The analysis was carried out visually on the basis of pattern
matching as described in following sections.
Polymer synthesis
1. The procedure is initiated with the thermal
decomposition of the blood sample. For this
purpose, the product is denatured by a standardized
method to carbohydrate chains and peroxide
compounds. During method validation, this was
confirmed by scanning electron microscopy (SEM)with energy dispersive x-ray spectrometry (EDX) for
particle characterization, using an automated
electron beam to monitor the laboratory process.
Electron microscopy provides not just visual
information about the organic and inorganic
submicron particles (size, shape, and morphology),
but also chemical identification as verified by x-ray
spectrometry [8].
2. The subsequent re-suspension of the collected
particles facilitates re-polymerization and the
crystallization into a solid form (i.e. based on the
previously formed polymer structures) as monomers
and crystals. The size of these monomers and
crystals is recorded as an in-process control.
Dynamic Light Scattering (using a Zeta-Size-Nano,
Malvern) is used to measure particle size. This
technique measures the diffusion of particles moving
under Brownian motion, and converts this to size
and a size distribution using the Stokes-Einstein
relationship. Non-Invasive Back Scatter technology
(NIBS) is incorporated to give the highest sensitivity
simultaneously with the highest dynamic size and
concentration range. The validated size of the
particles should be between 60 and 600 nanometers.
3. Insoluble residues are removed by filtration.
4. The filtrated supernatant is spread on prepared
slides for evaporation.
5. Following dehydration, the particles are precipitated
in complexes forming polymers and crystal textures.
6. These structures are analyzed microscopically and
documented digitally.
Pattern acquisition
To support easier standardization and validation, pat-
terns were acquired by a digital computer camera using
imaging software and analyzed visually for target struc-
tures using the same software (Zeiss Imaging Solutions
4.8″; Zeiss, Oberkochen, Germany). The pattern indicat-
ing polyps was experientially described and documented.
The truncated image shown in Figure 1 is representative
of the structures used in established visual PSP analysis.
Image analysis
Following microscopic image acquisition, textures and
patterns as used in visual examination had to be recog-
nized by image analysis. By using the LabImage platform
(Kapelan Bio-Imaging, Leipzig, Germany), an algorithm




From September 2011 to May 2012, 233 patients entered
the study. 9 physicians recruited the patients and recorded
Figure 1 Example findings representing structures considered typical for polyps (original magnification 25x) (a) shows all connected
structures while (b) shows the brim.
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(n = 216), and took blood samples (n = 233). Medical ex-
aminations were carried out on 233 patients. 45 patients
dropped out during statistical analysis (RS an PSP-test not
available (N = 3); RS not available (N = 14); RS: D + and
PSP-test not available (N = 22); RS: D- and PSP-test not
available (N = 6)). So the analysis set has an amount of
188. The results are comprised of 17 (7.3%) cases with
missing/unclear data, 165 (70.8%) cases with negative
results, and 51 (21.9%) with positive results. Out of these
patients, 33 had polyps confirmed by colonoscopy and





T- 99 62.3 8
T+ 60 37.7 21
All 159 100.0 29





Total 159 + 6 = 165 29 + 22 = 51 188 +
Prev:





PSP analysis could be carried out in 202 patients and re-
vealed 114 patients with a negative result (48.9%) and 88
patients with a positive result (37.8%) with colon polyp
specific structures identified, as shown in Table 1. Miss-
ing and unclear results were detected in 31 cases
(13.3%).
Image acquisition
The first criterion to identify a target structure is the
connection to the crystal brim in the microscopic image.
This criterion is necessary and structures not connectedondition) and test result (PSP-test), absolute and relative
All
D+




(width of Cl: 52.8%.. 87.3%)
(width of Cl: 54.2%.. 69.8%)
D+
28 = 216 Total 159 + 6 = 165 29 + 22 = 51
23.6%
(width of Cl: 30.5%.. 44.5%)
(width of Cl: 80.0%. 93.0%)
17
233
Figure 3 Description of the crystal patterns as tree-graphs (a).
Vertices are colored in (b), description of the colors in the text.
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they would otherwise fit the pattern criteria. Figure 1(a)
shows all connected structures for the image while
Figure 1(b) shows the brim. The pattern indicating
polyps can informally be described as one elongated stem
with rather short branches or teeth connected to the stem
that rarely or never branch out further (Figure 2).
To formalize the pattern, we used graph theoretic de-
scriptions [10]. We described the crystal patterns as tree-
graphs (Figure 3). A graph G= (V, E) is an ordered pair,
where V is the set of nodes (vertices, colored in Figure 3(b))
and E is the set of edges (black in Figure 3(b)) connecting
elements of V. We have only considered graphs where
e(u,v)∈E→u ≠ v (no loops) and multiple edges (different
edges connecting the same nodes) do not exist.
A graph T = (V, E) is a tree, if it contains no cycles and
is connected. A cycle is a path, where the first and the
last node of the sequence are the same. Two nodes u, v
∈ V are connected, if a path in T exists. A path is a se-
quence of nodes P = {v1,…vn}∈V with n ≥ 2 and for every
pair vi, vi+1;1 ≤ i < n - 1 there exists an edge e{ni,ni+1}∈ E
connecting those nodes. A graph is connected, if any
pair of distinct nodes in the graph is connected.
If we let T = (V, E) be the tree graph of a crystal pattern,
as shown in Figure 3(b), to describe the target structure
we need to define the root ρ of T, which is the node clos-
est to the brim (red node in Figure 3(b)). We define the
stem S(Vs, Es) of T as the path from ρ to one w ϵ V where
the length of the path is maximal maxi |P| = |ρ,…,vi|. Note
that there are at least two, maybe several nodes, w (de-
pending on the tree topology), where the length of the
path from the root is maximal. For our purpose, it doesFigure 2 Patterns indicating polyps. (a) and (b) show examples of the p
elongated stem with rather short branches or teeth connected to the stemnot matter, which w is chosen since if there are several
possible stems, the topology cannot fulfill the criterion as
mentioned below. In the example in Figure 3(b) the or-
ange colored node at the tip of the tree is chosen as w. We
now assign a distance labeling on the edges, where the
edges of the stem are labeled with 0, edges adjacent to the
stem with 1, edges adjacent to those with 2 and so on. For-
mally: d(e) = 0 if ϵ Es , also d(e{u, v}) = 1 if e ∉ Es, but either
u ∈ Vs or v ∈ Vs and d (e) =min (d(f{x, y}) + 1 where f ∈ E
and x = u or x = v or y = u or y = v.
In Figure 3(b) the trunk is comprised of the red, or-
ange, and yellow nodes as well as all edges connecting
them. Therefore, an edge, e, in Figure 3(b) connecting
yellow and green nodes is labeled with d(e) = 1 and anattern indicating that polyps can informally be described as one
which almost never branch out further (original magnification 100x).
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d(f ) = 2. The target structures are now characterized by
having a significant number of edges where (e) = 1,
which are also rather short if compared to the stem,
while there are few or no edges with d(f ) = 2 and no
edges with d(e) ≥ 3 present. A binary test yields “colon
polyp is present” vs “colon polyp is not present” as re-
sults. In addition, the result “not assessable” may occur.
Statistic description of PSP test characteristics
Results from 188 patients were included to establish a 2x2
table comparing the test results of the PSP analysis with
the results of suspicious cells from histological examina-
tions. As demonstrated in Table 1, 99 cases (62.3%) were
presented for type 1 (negative/negative), 8 cases (27.6%)
for type 2 (positive/negative), and 60 cases (37.7%) for type
3 (negative/positive). For type 4 (positive/positive) 21 cases
(72.4%) were presented. Taken together, a sensitivity of
72.4% (95%-CI: 52.8%-87.3%) and a specificity of 62.3%
(95%-CI: 54.2%-69.8%) could be proven.
As predictive values, a PPV of 37.2% (95%-CI: 30.5% –
44.5%) and a NPV of 88.0% (95%-CI: 80.0% - 93.0%)
were found. Hereby, a prevalence of 23.6% was assumed,
which is yielded when cases with known RS but missing
test results are taken into account additionally (see
Table 1, lower part). This prevalence is in coincidence
with known prevalence of polyps in German population.
The polymer structures can be represented qualitatively.
Similar to other crystallographic methods, unique pat-
terns are sought that occur specifically in relation with
the pathology. Rather than being measured as a quanti-
tative value, the patterns are looked at for qualitative
changes in both the shape and size of the crystals pro-
duced. Therefore, these are the only two options avail-
able for the evaluation.
Those subjects with adenoma-carcinoma activity in
the colon exhibit differentially expressed genes in the tis-
sue and exhibit changes in the concentration of various
substances in the whole blood which result from the
gene mutation typical for adenoma [11]. These cause a
change in the shape of the polymers, as described in the
Image Analysis section. Logically, subjects with such
structures exhibit a positive result (i.e. a serious suspi-
cion of adenoma polyps in the colon) while subjects
without such structures receive a negative result.
To check the operator dependency, the results of both
readers (in our case collaborators who evaluate the
structures) were compared. The results show that in 129
cases, reader 1 and reader 2 evaluated the structures
with “negative”, in 86 cases with “positive” while in only
14 (6.1%) of the cases did the readers give different re-
sults. In 93.9% of the cases, both readers reached the
same conclusion. These results strongly suggest that the
Polyp Specific Polymer analysis is operator-independent.Discussion
This study was undertaken to evaluate the diagnostic
accuracy of a new non-invasive diagnostic laboratory
methodology using routinely taken blood samples and
PSP to detect adenoma polyps. In patients undergoing
colonoscopy screening and histology examination, a sen-
sitivity of 72.4% and a specificity of 62.3% was proven. In
Western societies, malignant diseases are ranked as the
second leading cause of death with only cardiovascular
diseases ranked higher. Colorectal cancer (CRC) is the
third leading disease with an increasing incidence. The de-
tection of precursors at early stages of the disease is cru-
cial for reducing the CRC mortality rate. The incidence of
individuals choosing to undergo voluntarily the preventive
examination currently offered for everybody older than
55 years of age in Germany is very low. In fact, it is as low
as the sensitivity of the entirely non-invasive risk detection
method using stool tests. Despite the increase in public ac-
ceptance of FOB testing, there is no expected increase in
its sensitivity for detecting polyps.
Fecal occult blood testing
Fecal occult blood (FOB) testing is a simple, non-invasive
test that can be carried out by most primary care physi-
cians. There are several studies suggesting that annual
FOB testing, especially if combined with sigmoidoscopy
may decrease the mortality of colorectal cancer. In recent
years there has been some controversy regarding the ef-
fectiveness of the different types of FOB tests since in
general they are known to generate a high number of false
positives. In CRC screening trials, between 0.8% and 15%
of participants tested had a positive FOB test result while
55–65% of participants with a positive FOB test result
had no colorectal cancer or adenoma [12-15].
Original FOB tests, also called guaiac-based or gFOBT
detect the heme derived from blood in the stool. In
2001, a new class of FOB tests called Fecal Immuno-
chemical Tests (FIT) were introduced which detect glo-
bin in feces rather than heme. By detecting globin the
tests are both more sensitive and specific for lower levels
of gastrointestinal bleeding. Although these superior FIT
tests are now recommended in place of the traditional
annual standard guaiac FOBT, the older FOB tests are
still commonly used [16,17]. A comparative evaluation
of immunochemical fecal occult blood tests for colorec-
tal adenoma detection is presented in Table 2.
Virtual colonoscopy
Virtual colonoscopy is an exam used to detect changes or
abnormalities in the large intestine (colon) and rectum.
During virtual colonoscopy, computerized tomography
(CT) is used to produce hundreds of cross-sectional im-
ages of the abdominal organs. The images are combined
and digitally manipulated to provide a detailed view of the
Table 2 Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection [17]














Sensitivity % 5.4 35.8 29.6 11.4 18 45.2 58
Specificity % 95.9 81.9 81.8 96.7 92.9 70.2 58.8
Scatoscopy X X X X X X X
Blood
analysis
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copy, virtual colonoscopy does not require sedation or the
insertion of a scope into the colon. The high cost of CT
exams as a screening tool remains a negative factor.
Colonoscopy
For those patients who have tested positive for blood in
the feces (positive FOB or FIT test) colonoscopy is man-
datory. Colonoscopy is now accepted as the most accurate
method of detecting colonic polyps and also allows simul-
taneous removal of most lesions. Resected polyps are typ-
ically examined pathologically and categorized as benign
adenoma (tubular, tubulovillous, or villous), carcinoma
in situ, or invasive cancer. Appropriate follow-up testing,
usually colonoscopy, is mandatory for patients with posi-
tive results from their first examination. Since most cli-
nically significant colon polyps are located distal to the
splenic flexure, flexible sigmoidoscopy may be a reason-
able alternative to colonoscopy. However, lesions in the
right colon may go undetected and those patients found
to have a polyp on flexible sigmoidoscopy will conse-
quently also require a full colonoscopy, therefore being
subject to both tests [18-20].
PSP testing
PSP testing is a laboratory method based on thermal
denaturation of venous blood, followed by resuspension,
drying, and crystallographic read-out. Crystallographic
methods for the characterization of biological materials in
non-homogeneous, very complex bodily fluids have been
used in diagnostic investigation for a long time. Cerebro-
spinal fluid, saliva, and cervical mucus have been success-
fully treated crystallographically and subjected to various
types of diagnosis [21-25]. Currently developed proce-
dures of PSP analysis require qualitative analysis of the
microscopic textures by a laboratory physician (reader).
The patterns are associated with different pathological
processes. Their composition has been analyzed by elec-
tron microscopy and radiological measurements (SEM-EDX: Scanning electron microscopy (SEM) with energy
dispersive x-ray spectrometry (EDX) for particle charac-
terization using an automated electron beam) can be
used to monitor the production process. Electron mi-
croscopy provides not just visual information about the
organic and inorganic sub-micron particles (size, shape,
and morphology), but also chemical identification based
on the X-ray energy lines, empirical evaluations, and
biochemical methods. The complex electron micro-
scopic and radiological techniques are necessary only
during the research phase. Because the dehydrated end-
products’ optical structures are uniquely recognizable,
optical light microscopy can be used, which requires less
sample preparation.
The evaluation of the results arising from PSP analysis
involves processing large amounts of data, which has so
far been carried out visually on the basis of pattern
matching. However, to facilitate a wider adoption of PSP
and integration into daily practice it will be necessary to
validate the test through further laboratory testing [6].
Detecting relationships between disease patterns and
outcomes in polymer analysis is a major technological
challenge, because the analyzed structures can vary
greatly in shape, size, composition, and structure. Many
analytical methods that measure these textures therefore
only take an average over a large collection of them and
do not measure individual properties.
One of the unique characteristics of INDAGO’s meth-
odology is the ability to ensure stability in the pattern,
shape, size, composition, and structure throughout the
whole blood denaturation step, which had previously
been considered impossible. As a result, for the first time
it has been possible to develop a basic understanding of
the relationship between the analytical results and the
disease. This is time consuming and to some extent sub-
jective being strongly dependent on personal expertise.
Although INDAGO is in the process of automating the
evaluation process, for the purpose of this trial, two in-
dependent laboratory readers evaluated the results under
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curacy, the final result was derived according to the fol-
lowing rules: If the two readers agreed in a positive or
negative test result, this test result was used as final test
result. If the results of the two readers were different (e.g.
positive for reader 1 and “not assessable” for reader 2), the
final result was determined by an adjudication meeting of
the two readers. For the meeting, the aliquots (but not the
samples) were un-blinded by the TRM.
Therefore, approximately 220 tests were used for the
calculation of the primary and secondary endpoints. In
this study, PSP analysis, in relation to full colonoscopy
as the reference with its own sensitivity of around 80%,
offered a low-risk sensitivity of 72.4% at a specificity of
62.8%. We believe that this represents for the first time
the possibility to effectively identify the highest-risk can-
didates for endoscopy. This improved screening ad-
vances the ultimate aim of decreasing the incidence or
mortality of colorectal cancer in the selected population.
The high amount of false-positive PSP results may be due
to the relatively low sensitivity of colonoscopy (76% for
small polyps), which is considered the “Gold-Standard”
detection method. Significantly, PSP analysis has the
potential to conserve socio-economic resources by
identifying and subjecting more “right” and fewer
“wrong” patients to endoscopy and transferring them to
curative prevention via polypectomy or CRC early de-
tection. By combining the best-established, low-risk
screening elements with a blood test-based diagnostic
test such as PSP that has good acceptance, sensitivity,
and specificity, an increase in the reliable estimation of
a patient’s risk for CRC before colonoscopy is expected.
In the intermediate-term it is anticipated that public ac-
ceptance of colonoscopy will improve which will be a
major gain for preventative health care.
Based on the current schemes for follow-up or pre-
ventive controls, the introduction of a PSP blood test
would lead to better and more individualized patient
care. The test detects colon adenoma/carcinoma-specific
sequences of polymers individually, in any chosen time
interval. It is noteworthy that no adenocarcinoma case
was missed through PSP testing. In addition, sessile
polyps were detected with a good sensitivity. Using PSP
analysis, patient risk is extremely low since blood sam-
pling is generally considered, at least under normal cir-
cumstances, a “low risk” procedure.
According to the Robert Koch Institute, the average age
at which cancer is contracted is 73 (women) and 68 years
(men) [1]. Every year, in Germany more than 70,000 men
and women develop intestinal cancer and 30,000 die from
it. In October 2002, the legislature amended the provisions
of the law governing the early detection of intestinal can-
cer. Between 50 and 55 years of age one annual stool test
for concealed blood (FOBT) is offered.During their 56th year of life all statutory insurance
members are entitled to their first colonoscopy.
Due to fear, shame, uncertainty, repression, and lack
of knowledge this free offer is only utilized with
hesitation. Additionally occasional long waiting times
augment such personal reservations people may have
about the intestinal cleansing. Therefore, it is neces-
sary to take steps in order to increase the early
detection rate.
As a non-invasive method, the PSP-blood test is
patient-friendly and thus makes an important contribu-
tion to a wider acceptance of preventive measures and
the participation in regular preventive check-ups for in-
testinal cancer.
Equally important is that the PSP test detects high-risk
polyps, which left alone will directly lead to cancer. Re-
moving them is a very effective way to prevent colon
cancer from developing.
Colon polyps have been demonstrated through aut-
opsy studies to occur in more than 30% of people over
the age of 60 and in recent studies, large-scale screening
(more than 250,000) of asymptomatic German patients
over 55 demonstrated that 20% were found to have co-
lonic neoplasia s. This same study also showed that 7%
were diagnosed with advanced adenoma and invasive
cancer was demonstrated in 0.8% of the population [26].
Colon cancer represents one of the most important
causes of death in the elderly. Polyps are considered pre-
cancerous and causal for this disease. Despite a substantial
number of false-negative findings and generally poor ac-
ceptance by patients, screening is still performed by colon-
oscopy. In contrast, the relative non-invasiveness of PSP-
analysis, a novel blood based assay requiring only simple
blood collection, accords better patient acceptance as well
as providing a sensitive and selective means for the early
detection of colon polyps, particularly those high-risk
polyps which if left in situ can lead directly to cancer.
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